Capricor Therapeutics (CAPR) Tops Q2 EPS by 6c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.29), $0.06 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $3.92 million versus the consensus estimate of $3 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Capricor Therapeutics (CAPR) Misses Q2 EPS by 10c